

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

O I P E J C P A
OCT 20 2003
TRADEMARK OFFICE

ATTY. DOCKET NO.

18528.127

APPLICATION NO.

09/889,330

APPLICANTS

Andrew A. YOUNG *et al.*

371 FILING DATE

December 27, 2001

ART UNIT

1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	PUBLICATION DATE	NAME	CLASS	SUB- CLASS	FILING DATE
SWL	AA1	6,506,724 B1	1/2003	Hiles <i>et al.</i>		
SWL	AB1	US 2003/ 0087821 A1	5/2003	Beeley <i>et al.</i>		

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

SWL	AC1	AMYLIN PHARMACEUTICALS, INC., Form 10-K "Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, March 15, 2002, pages 1-8.				
	AD1	Baggio <i>et al.</i> , "Sustained Expression of Exendin-4 Does Not Perturb Glucose Homeostasis, β -Cell Mass, or Food Intake in Metallothionein-Preproexendin Transgenic Mice," <i>J. Biol. Chem.</i> 275(44):34471-7 (2000).				
	AF1	Edwards <i>et al.</i> , "Exendin-4 Reduces Fasting and Postprandial Glucose and Decreases Energy Intake in Healthy Volunteers," <i>Am. J. Physiol. Endocrinol. Metab.</i> 281:E155-61 (2001).				
	AG1	Egan <i>et al.</i> , "The Insulinotropic Effect of Acute Exendin-4 Administered to Humans: Comparison of Nondiabetic State to Type 2 Diabetes," <i>J. Clin. Endocrinol. & Metab.</i> 87(3):1282-90 (2002).				
	AH1	Goke <i>et al.</i> , "Exendin-4 Is a High Potency Agonist and Truncated Exendin-(9-39)-amide an Antagonist at the Glucagon-like Peptide 1-(7-36)-amide Receptor of Insulin-secreting β -Cells," <i>J. Biol. Chem.</i> 268(26):19650-55 (1993) (previously submitted on August 20, 2002).				
	AI1	International Search Report, International Application No. PCT/US03/16699 (August 2003)				
SWL	AJ1	Tourrel <i>et al.</i> , "Persistent Improvement of Type 2 Diabetes in the Goto-Kakizaki Rat Model by Expansion of the β -Cell Mass During the Prediabetic Period with Glucagon-Like Peptide-1 or Exendin-4," <i>Diabetes</i> 51:1443-52 (2002).				

EXAMINER

DATE CONSIDERED

5-5-04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

RECEIVED
OCT 21 2003
TECH CENTER 1600/2900



Please type a plus sign (+) inside this box



Approved for use through 10/31/2002 PTO/SB/08A (10-01)

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	09/889,330
Filing Date	January 14, 2000
First Named Inventor	Young
Art Unit	1614
Examiner Name	TBA
Attorney Docket Number	030639.0027.UTL1

Sheet 1 of 4

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	U.S. Patent Document		Publication Date MMDDYYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
SWL	AA	5,424,286		06-13-1995	Eng	

FOREIGN PATENT DOCUMENTS


Examiner Initials *	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴ - Kind Code ⁵ (if known)				
SWL	AB	WO	97/46584	12-11-1997	Boehringer Mannheim GmbH	Cited in International Search Report (copy attached)	
SWL	AC	WO	98/08871	03-05-1998	Novo Nordisk A/S		
SWL	AD	WO	98/30231	07-16-1998	Amylin Pharmaceuticals, Inc.		
SWL	AE	WO	99/07404	02-18-1999	Amylin Pharmaceuticals, Inc.		
SWL	AF	WO	99/25727	05-27-1999	Amylin Pharmaceuticals, Inc.		
SWL	AG	WO	99/25728	05-27-1999	Amylin Pharmaceuticals, Inc.		
SWL	AH	WO	99/40788	08-19-1999	Amylin Pharmaceuticals, Inc.		
SWL	AI	WO	99/43708	09-02-1999	Novo Nordisk A/S		

Examiner Signature		Date Considered	5-5-04
--------------------	--	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please sign (+) inside this box



PTO/SB/08 (10-01)
Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	09/889,330
Filing Date	January 14, 2000
First Named Inventor	Young
Art Unit	1614
Examiner Name	TBA
Attorney Docket Number	030639.0027.UTL1

Sheet	2	of	4
-------	---	----	---

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
SWL	AJ	BHAVSAR et al., "Inhibition of Gastric Emptying and of Food Intake Appear to be Independently Controlled in Rodents," 25 th Annual Meeting, November 11-16, 1995, San Diego, California, <u>Soc. Neurosci.</u> , 21:460 (Abstract) (188.8) (1995)	
	AK	D'ALESSIO et al., "Elimination of the Action of Glucagon-like Peptide 1 Causes an Impairment of Glucose Tolerance after Nutrient Ingestion by Healthy Baboons," <u>J. Clin. Invest.</u> , 97(1):133-38 (1996)	
	AL	DANIEL et al., "Use of Glucagon in the Treatment of Acute Diverticulitis," <u>British Medical Journal</u> , 3:720-2 (1974)	
	AM	EISSELE et al., "Rat Gastric Somatostatin and Gastrin Release: Interactions of Exendin-4 and Truncated Glucagon-Like Peptide-1 (GLP-1) Amide," <u>Life Sci.</u> , 55(8):629-34 (1994)	
	AN	ENG, "Prolonged Effect of Exendin-4 on Hyperglycemia of db/db Mice," <u>Diabetes</u> , 45(Supp 2):152A (abstract 554) (1996)	
	AO	ENG et al., "Purification and Structure of Exendin-3, a New Pancreatic Secretagogue Isolated from <i>Heloderma horridum</i> Venom," <u>J. Biol. Chem.</u> , 265(33):20259-62 (1990)	
	AP	ENG et al., "Isolation and Characterization of Exendin-4, an Exendin-3 Analogue, from <i>Heloderma suspectum</i> Venom," <u>J. Biol. Chem.</u> , 267(11):7402-5 (1992)	
	AQ	GLAUSER et al., "Intravenous Glucagon in the Management of Esophageal Food Obstruction," <u>J. Am. Coll. Emer. (JACEP)</u> , 8(6):228-231 (1979)	
	AR	GOKE et al., "Exendin-4 Is a High Potency Agonist and Truncated Exendin-(9-39)-amide an Antagonist at the Glucagon-like Peptide 1-(7-36)-amide Receptor of Insulin-secreting β -Cells," <u>J. Biol. Chem.</u> , 268(26):19650-55 (1993)	
SWL	AS	KOLLIGS et al., "Reduction of the Incretin Effect in Rats by the Glucagon-Like Peptide 1 Receptor Antagonist Exendin(9-39) Amide," <u>Diabetes</u> , 44:16-19 (1995)	
SWL	AT	MONTROSE-RAFIZADEH et al., "Structure-function Analysis of Exendin-4 /	

Examiner Signature		Date Considered	5-5-04
--------------------	--	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED

AUG 23 2002

TECHNICAL
1600/2000

Please () plus sign (+) inside this box

PTO/SB/08A (10-01)
Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	09/889,330
				Filing Date	January 14, 2000
				First Named Inventor	Young
				Art Unit	1614
				Examiner Name	TBA
Sheet	3	of	4	Attorney Docket Number	030639.0027.UTL1

		GLP-1 Analogs," <u>Diabetes</u> , 45(Suppl. 2):152A (1996) [abstract 553]	
SWL	AU	O'HALLORAN et al., "Glucagon-like Peptide-1 (7-36)-NH ₂ : a Physiological Inhibitor of Gastric Acid Secretion in Man," <u>J. Endocrinol.</u> , 126(1):169-73 (1990)	
	AV	ØRSKOV et al., "Biological Effects and Metabolic Rates of Glucagonlike Peptide-1 7-36 Amide and Glucagonlike Peptide-1 7-37 in Healthy Subjects Are Indistinguishable," <u>Diabetes</u> , 42:658-61 (1993)	
	AW	RAUFMAN et al., "Exendin-3, a Novel Peptide from <i>Heloderma horridum</i> Venom, Interacts with Vasoactive Intestinal Peptide Receptors and a Newly Described Receptor on Dispersed Acini from Guinea Pig Pancreas," <u>J. Biol. Chem.</u> , 266(5):2897-902 (1991)	
	AX	RAUFMAN et al., "Truncated Glucagon-like Peptide-1 Interacts with Exendin Receptors in Dispersed Acini from Guinea Pig Pancreas", <u>J. Biol. Chem.</u> 267(30):21432-37 (1992)	
	AY	SCHEPP et al., "Exendin-4 and Exendin-(9-39)NH ₂ : Agonist and Antagonist, Respectively, at the Rat Parietal Cell Receptor for Glucagon-like Peptide-1-(7-36)NH ₂ ," <u>Eur. J. Pharm.</u> , 269:183-91 (1994)	
	AZ	SCHJOLDAGER et al., "GLP-1 (Glucagon-like Peptide 1) and Truncated GLP-1, Fragments of Human Proglucagon, Inhibit Gastric Acid Secretion in Humans," <u>Digest. Dis. Sci.</u> , 34(5):703-8 (1989)	
	BA	STOWER et al., "A Trial of Glucagon in the Treatment of Painful Biliary Tract Disease," <u>Brit. J. Surg.</u> , 69:591-2 (1982)	
	BB	THORENS et al., "Cloning and Functional Expression of the Human Islet GLP-1 Receptor," <u>Diabetes</u> , 42(11):1678-82 (1993)	
	BC	THORENS, "Expression Cloning of the Pancreatic β Cell Receptor for the Gluco-incretin Hormone Glucagon-like Peptide 1," <u>P. Natl. Acad. Sci. USA</u> , 89:8641-45 (1992)	
	BD	TURTON et al., "A Role for Glucagon-like Peptide-1 in the Central Regulation of Feeding," <u>Nature</u> , 379(6560):69-72 (1996)	
SWL	BE	WANG et al., "Glucagon-like Peptide-1 Is a Physiological Incretin in Rat," <u>J. Clin. Invest.</u> , 95:417-21 (1995)	

Examiner Signature		Date Considered	5-5-04
--------------------	--	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box



PTO/SB/08A (10-05)
Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	4	of	4	Attorney Docket Number	030639.0027.UTL1
-------	---	----	---	------------------------	------------------

Complete if Known	
Application Number	09/889,330
Filing Date	January 14, 2000
First Named Inventor	Young
Art Unit	1614
Examiner Name	TBA

SWL	BF	WETTERGREN et al., "Truncated GLP-1 (Proglucagon 78-107-Amide) Inhibits Gastric and Pancreatic Functions in Man," <u>Digest. Dis. Sci.</u> , 38(4):665-73 (1993)	
SWL	BG	WILLMS et al., "Gastric Emptying, Glucose Responses, and Insulin Secretion after a Liquid Test Meal: Effects of Exogenous Glucagon-Like Peptide-1 (GLP-1)-(7-36) Amide in Type 2 (Noninsulin-Dependent) Diabetic Patients," <u>J. Clin. Endocrinol. Metab.</u> , 81(1):327-32 (1996)	

Examiner Signature		Date Considered	5-5-04
--------------------	--	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231.
NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED
AUG 23 2002
TECH C 1602/2000